Name | UCM-1306 |
---|
Description | UCM-1306 is a potent and orally active human dopamine D1 receptor allosteric modulator (PAM). UCM-1306 increases the endogenous dopamine (DA) maximal effect both in human and mouse D1 receptors. UCM-1306 not only for improving motor symptoms but also for addressing the key comorbid cognitive impairment associated with long-term Parkinson’s disease (PD)[1]. |
---|---|
Related Catalog | |
In Vitro | UCM-1306 (2-(Fluoromethoxy)-4'-(S-methylsulfonimidoyl)-1,1'-biphenyl; 1-10 μM) 以浓度-响应的方式增强 cAMP,且 EC50=60 nM。 |
In Vivo | UCM-1306 (2-(Fluoromethoxy)-4'-(S-methylsulfonimidoyl)-1,1'-biphenyl; 5 mg/kg; p.o.; C57BL/6J 小鼠) 具有良好的脑穿透性和口服可用性。血浆浓度可在 8 小时内定量,Tmax 为 0.5 小时[1]。 UCM-1306 (1 mg/kg; ip) 增强成年小鼠可卡因诱导的过度运动[1]。 UCM-1306 (1 mg/kg; ip) 有助于巩固长期记忆的形成[1]。 . Animal Model: Adult C57BL/6J mice with cocaine-induced hyperactivity model[1] Dosage: 1 mg/kg; cocaine (20 mg/kg, sc) Administration: Intraperitoneal injection Result: Increased cocaine-induced hyperlocomotion, suggesting an in vivo potentiation of DA action at the D1R. Animal Model: Adult C57BL/6J mice Dosage: 1 mg/kg Administration: Intraperitoneal injection Result: Increased memory trace in C57BL/6J mice. |
References |
Molecular Formula | C14H14FNO2S |
---|---|
Molecular Weight | 279.33 |